News Sentiment

IMDX sentiment intelligence

Insight Molecular Diagnostics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 4.74 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.7% over one week, -12.9% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -6.7% Price reacting lower
Trend fit Trend inactive -12.9% over four weeks
Fair value 30.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 34
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Ad-hoc-news.de 8
TradingView 6
GlobeNewswire 6
Quiver Quantitative 4
Market source 4
Insider Monkey 3
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 13
Macro sensitivity 1
Analyst action 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53
TradingKey Direct company coverage

Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Insight Molecular Diagnostics Ord Shs (IMDX), including future EPS and revenue growth estimates. Based on 4 analysts, the current rating is a "Buy" with a target price upside of 53.19%. The company's expected revenue for the next qua

Tone
Positive 67/100
Event
Earnings
Published
22 Jun 2026 06:40
Source
TradingKey
Insider Monkey Direct company coverage

Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment

Insight Molecular Diagnostics Inc. (IMDX) recently announced publication of new data for its GraftAssure transplant rejection monitoring assay, demonstrating its statistical superiority and correlation with kidney transplant rejection. This development comes as BTIG maintains a N

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 18:40
Source
Insider Monkey
Insider Monkey Direct company coverage

12 High-Growth Micro-Cap Stocks to Buy Now

This article lists high-growth micro-cap stocks, focusing on Insight Molecular Diagnostics Inc. (IMDX) as one such opportunity. It highlights IMDX's GraftAssure transplant rejection monitoring assay, its statistical superiority, and upcoming discussions at the American Transplant

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 12:14
Source
Insider Monkey
Stock Titan Direct company coverage

IMDX SEC Filings - Insight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of Insight Molecular Diagnostics Inc. (IMDX) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents. It highlights recent filings detailing a significant option grant to CEO Josh Riggs and salary increases for the CEO and CFO. The

Tone
Positive 59/100
Event
Market update
Published
18 Jun 2026 01:09
Source
Stock Titan
Stock Titan Direct company coverage

Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase

Insight Molecular Diagnostics Inc. (IMDX) shareholders approved all proposals at their 2026 annual meeting, including the election of four directors, the ratification of CBIZ CPAs P.C. as the accounting firm, and the approval of executive officer compensation on an advisory basis

Tone
Neutral 50/100
Event
Regulatory and legal
Published
17 Jun 2026 20:09
Source
Stock Titan
Sahm Direct company coverage

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Insight Molecular Diagnostics Inc. (iMDx) announced the publication of a study in Clinical Chemistry demonstrating high concordance between its GraftAssure™ transplant monitoring test and a leading NGS-based assay. GraftAssure™ showed 99.2% agreement and improved analytical sensi

Tone
Positive 71/100
Event
Market update
Published
16 Jun 2026 21:09
Source
Sahm
Stock Titan Direct company coverage

New lab test rivals DNA sequencing to monitor kidney transplants

Insight Molecular Diagnostics (IMDX) announced positive head-to-head data for its GraftAssure transplant monitoring test, published in Clinical Chemistry. The study showed 99.2% agreement with a leading next-generation sequencing (NGS) assay for kidney rejection risk assessment,

Tone
Positive 71/100
Event
Market update
Published
16 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity

Insight Molecular Diagnostics Inc. (IMDX) director Andrew J. Last reported receiving 26,943 Restricted Stock Units (RSUs) at a price of $0.00, increasing his direct holdings to 66,452 shares. These RSUs will vest at the next annual shareholders' meeting, contingent on his continu

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 22:09
Source
Stock Titan